Payment overview · 2025
General Payments
$1,373.63
80 reported records · 22 companies
Healthcare provider profile · identity verified
Christopher John Oldfield, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAVANNAH, GA · NPI 1073512877
Verified facts
What the public records show
CMS Open Payments records show Christopher John Oldfield, M.D. received $1,373.63 in general payments during 2025 across 80 reported records.
Amgen Inc. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 999 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $231.88 | 16.9% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $223.98 | 16.3% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.67 | 10.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $114.37 | 8.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.64 | 8.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.81 | 6.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $89.15 | 6.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.18 | 3.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.22 | 3.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.43 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.98 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.84 | 1.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.90 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.79 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.05 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.76 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.06 | 1.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.96 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.64 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.79 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.01 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,373.63 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.64 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.26 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.26 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.37 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.31 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.31 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.48 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.79 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $91.81 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $75.79 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $71.74 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.83 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $57.59 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.03 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.22 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.43 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.53 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 309 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 228 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
130 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
309 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 24 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
999 | 69 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2871 | 309 |
| Amlodipine Besylate | Amlodipine Besylate | 2500 | 260 |
| Furosemide | Furosemide | 1553 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1413 | 149 |
| Gabapentin | Gabapentin | 1361 | 135 |
| Divalproex Sodium | Divalproex Sodium | 1172 | 74 |
| Trazodone Hcl | Trazodone Hcl | 1131 | 123 |
| Potassium Chloride | Potassium Chloride | 1094 | 107 |
| Eliquis | Apixaban | 999 | 69 |
| Carvedilol | Carvedilol | 984 | 82 |
| Sertraline Hcl | Sertraline Hcl | 972 | 90 |
| Famotidine | Famotidine | 971 | 79 |
| Quetiapine Fumarate | Quetiapine Fumarate | 939 | 54 |
| Levetiracetam | Levetiracetam | 918 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 869 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 846 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 844 | 146 |
| Losartan Potassium | Losartan Potassium | 826 | 77 |
| Metformin Hcl | Metformin Hcl | 826 | 114 |
| Mirtazapine | Mirtazapine | 728 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 720 | 82 |
| Lisinopril | Lisinopril | 681 | 92 |
| Omeprazole | Omeprazole | 676 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 645 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 622 | 149 |
| Tramadol Hcl | Tramadol Hcl | 574 | 116 |
| Escitalopram Oxalate | Escitalopram Oxalate | 530 | 68 |
| Donepezil Hcl | Donepezil Hcl | 528 | 45 |
| Allopurinol | Allopurinol | 485 | 48 |
| Meloxicam | Meloxicam | 480 | 120 |
| Simvastatin | Simvastatin | 434 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 401 | 37 |
| Buspirone Hcl | Buspirone Hcl | 400 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 389 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 47 |
| Lorazepam | Lorazepam | 332 | 64 |
| Tizanidine Hcl | Tizanidine Hcl | 329 | 83 |
| Xarelto | Rivaroxaban | 328 | 21 |
| Baclofen | Baclofen | 321 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 321 | 65 |
| Ropinirole Hcl | Ropinirole Hcl | 318 | 23 |
| Risperidone | Risperidone | 315 | 24 |
| Farxiga | Dapagliflozin Propanediol | 309 | 37 |
| Methenamine Hippurate | Methenamine Hippurate | 305 | 11 |
| Olanzapine | Olanzapine | 288 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 267 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 260 | 49 |
| Pregabalin | Pregabalin | 257 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 252 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 248 | 26 |
| Montelukast Sodium | Montelukast Sodium | 236 | 60 |
| Jardiance | Empagliflozin | 228 | 24 |
| Memantine Hcl | Memantine Hcl | 221 | 16 |
| Finasteride | Finasteride | 220 | 22 |
| Spironolactone | Spironolactone | 220 | 32 |
| Lacosamide | Lacosamide | 203 | 13 |
| Bumetanide | Bumetanide | 201 | 25 |
| Ziprasidone Hcl | Ziprasidone Hcl | 201 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 197 | suppressed |
| Clonazepam | Clonazepam | 195 | 27 |
| Januvia | Sitagliptin Phosphate | 186 | 11 |
| Celecoxib | Celecoxib | 185 | 39 |
| Lamotrigine | Lamotrigine | 185 | 14 |
| Ezetimibe | Ezetimibe | 184 | 25 |
| Latanoprost | Latanoprost | 180 | 32 |
| Primidone | Primidone | 179 | 13 |
| Fenofibrate | Fenofibrate | 176 | 18 |
| Aripiprazole | Aripiprazole | 175 | 18 |
| Alprazolam | Alprazolam | 173 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 173 | 49 |
| Metformin Hcl Er | Metformin Hcl | 173 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 172 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 171 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 164 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 162 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 162 | 35 |
| Oxcarbazepine | Oxcarbazepine | 158 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 149 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 145 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 140 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 137 | 45 |
| Ozempic | Semaglutide | 135 | 34 |
| Carbamazepine | Carbamazepine | 134 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 131 | suppressed |
| Myrbetriq | Mirabegron | 130 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 58 |
| Diazepam | Diazepam | 121 | 27 |
| Methylprednisolone | Methylprednisolone | 121 | 96 |
| Nifedipine Er | Nifedipine | 121 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 116 | 12 |
| Glycopyrrolate | Glycopyrrolate | 116 | suppressed |
| Atenolol | Atenolol | 115 | 17 |
| Novolog Flexpen | Insulin Aspart | 112 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 111 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 29 |
| Azithromycin | Azithromycin | 108 | 87 |
| Bupropion Xl | Bupropion Hcl | 106 | 21 |
| Gemtesa | Vibegron | 105 | suppressed |
| Linzess | Linaclotide | 102 | 19 |
| Glipizide | Glipizide | 101 | 12 |
| Prednisone | Prednisone | 101 | 33 |
| Glipizide Er | Glipizide | 100 | 27 |
| Haloperidol | Haloperidol | 99 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 99 | 15 |
| Mounjaro | Tirzepatide | 96 | 14 |
| Telmisartan | Telmisartan | 94 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 93 | 22 |
| Valacyclovir | Valacyclovir Hcl | 93 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 90 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 87 | 61 |
| Valproic Acid | Valproic Acid | 87 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | suppressed |
| Valsartan | Valsartan | 84 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 83 | 62 |
| Rivastigmine | Rivastigmine Tartrate | 82 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 81 | 12 |
| Cephalexin | Cephalexin | 81 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 81 | suppressed |
| Levofloxacin | Levofloxacin | 78 | 64 |
| Chlorthalidone | Chlorthalidone | 77 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 75 | 18 |
| Digoxin | Digoxin | 73 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 19 |
| Ondansetron Odt | Ondansetron | 69 | 26 |
| Humalog Kwikpen U-100 | Insulin Lispro | 65 | suppressed |
| Dutasteride | Dutasteride | 63 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 29 |
| Lactulose | Lactulose | 62 | 12 |
| Prazosin Hcl | Prazosin Hcl | 62 | suppressed |
| Roflumilast | Roflumilast | 62 | suppressed |
| Carbamazepine Er | Carbamazepine | 61 | suppressed |
| Ingrezza | Valbenazine Tosylate | 61 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 15 |
| Ibuprofen | Ibuprofen | 58 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 57 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 57 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 56 | suppressed |
| Estradiol | Estradiol | 55 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Zonisamide | Zonisamide | 55 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | suppressed |
| Methazolamide | Methazolamide | 53 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 14 |
| Amantadine | Amantadine Hcl | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Novolog | Insulin Aspart | 52 | 15 |
| Topiramate | Topiramate | 52 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 49 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 36 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Sucralfate | Sucralfate | 47 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 45 | 12 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | suppressed |
| Movantik | Naloxegol Oxalate | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 13 |
| Risperdal Consta | Risperidone Microspheres | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 27 |
| Modafinil | Modafinil | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Colchicine | Colchicine | 39 | 11 |
| Nystatin | Nystatin | 38 | 31 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 37 | 20 |
| Lithium Carbonate | Lithium Carbonate | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Doxepin Hcl | Doxepin Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Clonidine | Clonidine | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 14 |
| Haloperidol Decanoate | Haloperidol Decanoate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 27 | suppressed |
| Risperidone Er | Risperidone Microspheres | 27 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Levemir | Insulin Detemir | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | 11 |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 15 |
| Descovy | Emtricitabine/Tenofov Alafenam | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | 13 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 25 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Dexamethasone | Dexamethasone | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 17 |
| Mitigare | Colchicine | 24 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 24 | suppressed |
| Alphagan P | Brimonidine Tartrate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Tivicay | Dolutegravir Sodium | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Admelog | Insulin Lispro | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Insulin Aspart | Insulin Aspart | 19 | 12 |
| Santyl | Collagenase Clostridium Hist. | 19 | 14 |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 13 |
| Etodolac Er | Etodolac | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Abilify Maintena | Aripiprazole | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Felodipine Er | Felodipine | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Tresiba | Insulin Degludec | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Insulin Degludec | Insulin Degludec | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Vardenafil Hcl | Vardenafil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,373.63 · 80 records | Amgen Inc. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, INTERSTIM, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error